Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- ...
Read moreFinal analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- ...
Read moreSanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation ...
Read moreSanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), ...
Read moreAs part of a long-standing commitment to reduce the environmental footprint of the company’s products and ...
Read moreA pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not ...
Read moreTwo-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants A booster study ...
Read moreLibtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung ...
Read moreAdjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups High immune response after a single dose in patients with prior ...
Read moreSanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the ...
Read moreNirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season. Nirsevimab met its Phase ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.